16 FEB 2022
U.S. Life Sciences Real Estate Investment Market Poised for Further Growth in 2022
Investment in U.S. life sciences real estate increased by 62 percent last year, with further growth of at least 10 percent expected in 2022, according to a CBRE research report.
Investment in life sciences real estate, comprised of lab and Research and Development (R&D) properties, reached $21.4 billion in 2021, a 62 percent increase over 2020. Investment in the sector has grown by 111 percent since 2018.
“The surge in investment in the U.S. life sciences market is underpinned by strong supply and demand fundamentals,” said Chris Bodnar, Vice Chairman and Co-Head of Healthcare & Life Sciences Capital Markets at CBRE. “A shortage of existing life sciences space available for purchase, coupled with robust and soaring property prices, have led most real estate investors focused on this sector to pursue development opportunities.”
Read the full report here.
For more information, please contact:
CBRE Healthcare & Life Sciences Capital Markets
Chris Bodnar
Vice Chairman
+1 303 628 1711
chris.bodnar@cbre.com
Lee Asher
Vice Chairman
+1 404 504 5965
lee.asher@cbre.com
Ryan Lindsley
Senior Director
+1 303 628 1745
ryan.lindsley@cbre.com
Jordan Selbiger
Senior Director
+1 404 923 1259
jordan.selbiger@cbre.com
Cole Reethof
Associate Director
+1 404 504 7864
cole.reethof@cbre.com
CBRE Healthcare & Life Sciences Debt & Structured Finance
Sabrina Solomiany
First Vice President
+1 404 536 5054
sabrina.solomiany@cbre.com
Zack Holderman
Senior Vice President
+1 858 337 9412
zack.holderman@cbre.com
Jesse Greshin
Senior Analyst
+1 860 808 4810
jesse.greshin@cbre.com
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
